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doi:10.1016/j.kjms.2011.05.010Abstract Arsenic is a proven human carcinogen. Although the mechanism of its carcinogeni-
city is still largely unknown, methylation is thought to have an important role to play in arsenic
toxicity. In this study, urinary methylation profiles were investigated in female C57BL/6J black
mice given drinking water containing 500 mg arsenate (AsV)/L, 250 mg AsV/L, or 100 mg AsV/L as
sodium arsenate for 2 months. The concentrations of arsenic chosen reflected those in the
drinking water often encountered in arsenic-endemic areas. Urine samples were collected
from the mice at the end of the exposure period, and the arsenic species were analyzed by
high performance liquid chromatography-inductively coupled plasma-mass spectrometry. All
detectable arsenic species showed strong linear correlation with the administered dosage.
The methylation patterns were similar in all three groups with a slight decrease of dimethylar-
sinic acid/AsV ratio in the 500-mg/L group, which corresponded to the significantly higher
arsenic retention in the tissue. The results indicate that urinary arsenic could be used as a good
biomarker for internal dose and potential biological effects. Different doses of arsenic expo-
sure could result in different degrees of methylation, excretion, and tissue retention, and this
may contribute to the understanding of arsenic carcinogenicity.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.search Centre for Environmental Toxicology, 39 Kessels Road, Coopers Plains, Brisbane, Qld 4108,
.C. Ng).
vier Taiwan LLC. All rights reserved.
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Inorganic arsenic (iAs) is classified as Group I carcinogen
primarily based on strong epidemiological data [1e3]. As
ubiquitous environmental toxicants and carcinogens,
arsenicals pose significant health impacts on both humans
and animals. It has been estimated that up to 100 million
people globally are at risk as a result of drinking arsenic-
contaminated waters [4,5].
In mammals, iAs is methylated to its less harmful
metabolites, monomethylarsonic acid (MMAV) and dimethy-
larsinic acid (DMAV), which are then excreted in the urine
together with the unmetabolized iAs, including arsenate
(AsV) and arsenite (AsIII). A simplified scheme of arsenic
metabolism in mammals, including humans, is given in the
work by Kitchin [6]. The reduction from pentavalent to
trivalent arsenic states may occur enzymatically or non-
enzymatically through glutathione. Oxidation and methyla-
tion are coupled in arsenic metabolism with the trivalent
arsenic as the substrate and the more methylated pentava-
lent arsenic as the product. Monomethylarsonous acid
(MMAIII) and dimethylarsinous acid (DMAIII) have been found
in the urine of humans chronically exposed to iAs through
drinking water [7,8]. Similar metabolites were also found in
the bile of rats administrated with AsIII intravenously [9].
MMAIII is more toxic to hepatocytes in vitro, whereas DMAIII is
380-fold more genotoxic than iAs [10]. This suggests that the
previous thought of arsenic metabolism by stepwise meth-
ylation as a detoxification pathway is now questionable.
However, the precise role of these toxic metabolic inter-
mediates in arsenic carcinogenicity is yet to be elucidated.
Recently, MMAIII was proved to be carcinogenic to mice [11].
The World Health Organizationerecommended guideline
value for arsenic in drinking water is 10 mg/L, whereas the
value in Australia is 7 mg/L. However, many developing
countries still have their standards set at 50 mg/L. It is
generally regarded that levels greater than 50 mg/L of
arsenic in drinking water is not protective for human health
[12]. Notably, World Health Organization/Food and Agri-
culture Organisation of the United Nations has withdrawn
its provisional tolerable weekly intake of 0.015 mg As/kg
body weight (bw) at the 72nd Joint Expert Committee of
Food Additives meeting recently [13].
There are substantial variations in the susceptibility to
arsenic intoxication among individuals, which may probably
be related to differences in their capacities to metabolize
arsenic. Most population groups studied so far have an
average of 10e30% iAs, 10e20% MMA, and 60e70% DMA in
their urine samples, with considerable interindividual vari-
ations [14]. Significantly, recent studies have identified
population groups with unusually low or high urinary excre-
tion of MMA. It is conceivable that a genetic polymorphism
may exist in the biomethylation of arsenic. Over and above
these, the rates of methylation of arsenic have also been
found to vary considerably among animal species [15,16].
For example, mice exposed to iAs excrete 90% of the
administered dose in 2 days, of which almost 80% is DMA [17].
A similarly high degree ofmethylation has also been reported
for dogs, rabbits, and guinea pigs exposed to AsV [18e21].
It is apparent that the efficient methylation of arsenic in
these experimental animals may have led to faster tissueclearance and less toxic effects. For comparison, the bio-
logical half-time of arsenic in humans is in the order of 4 days
[22]. It should be noted that the rats have efficient methyl-
ation capacity of arsenic, but most of the DMA produced is
retained in the erythrocytes, resulting in a slower rate of
excretion in the urine [23]. In contrast, some animal species
(e.g. the marmoset monkey and the chimpanzee) appear to
lack the ability to methylate iAs [20,24].
In this study, we examine the possibility of using the
mouse as an animal model for elucidating the metabolism
of subchronic arsenic exposure. In this context, the arsenic
methylation processes in the mouse and human beings are
compared. There is some information available from
previous short-term studies in which relatively high arsenic
dose was used. Thus, it would be instructive to study the
urinary methylation profile in mice subchronically exposed
to low doses of arsenic in the drinking water, as such
exposure regimens/scenarios are similar to those of human
exposure to arsenic in endemic areas.
Materials and methods
Reagents
Sodium arsenate and sodium arsenite were purchased from
Ajax Chemical, Sydney, Australia. Mixed arsenic standards
and internal standards for high performance liquid chroma-
tography-inductively coupled plasma-mass spectrometry
(HPLC-ICP-MS) analysis were purchased from Agilent Tech-
nologies, Victoria, Australia. All chemicals were of analyt-
ical-reagent grade unless stated otherwise. Mixed standards
containing four arsenic species (AsIII, AsV, MMAV, and
DMAV) were prepared with concentrations of 1 mg/L, 3 mg/L,
5 mg/L, 10 mg/L, 15 mg/L, 20 mg/L, and 40 mg/L for arsenic
speciation [25].
Animals and treatment
Animal care was provided in accordance with the institu-
tional animal ethicseapproved protocol (Animal Ethics
Committee No.: NRC 2/99/19). Female C57BL/6J black
mice, aged 4 weeks, were divided into groups of 15, with
five mice per cage, and were given drinking water con-
taining 500 mg AsV/L, 250 mg AsV/L, or 100 mg AsV/L as
sodium arsenate ad libitum for 2 months. Groups of 15
control mice were given demineralized water containing
less tan 0.1 mg As/L. The arsenic solution was prepared
every 2 weeks and stored in polypropylene container under
animal house condition. The arsenic concentration of the
drinking water was monitored by HPLC-ICP-MS (see details
later). The mice were fed with a commercial rodent diet
(Norco, Brisbane, Australia). All animals were kept in
standard polypropylene cages with stainless steel wiree
mesh tops equipped with polycarbonate plastic drinking
bottles with stainless steel sip tubes. The animal caring
facility is operated at controlled temperature set at
21e23C, 13 filtered air changes per hour, 12-hour/12-hour
light and dark cycle, and year-round relative humidity of
about 60%. The volume of the drinking water consumed and
bw of each mouse were measured weekly. Each cage of five
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Figure 1. Changes in body weight (g; mean standard error)
of female C57BL/6J mice continually exposed to different
concentrations of arsenate in drinking water (nZ 15 for each
group).
Subchronic exposure of arsenic to mice 419mice was kept in a metabolic cage for 24-hour urine
collection at the end of 2 months’ exposure. All samples
were stored at 80C until analysis.
Urinary arsenic speciation by HPLC-ICP-MS
Equipment
Arsenic species were measured using an HPLC-ICP-MS system
based on a previously published method [25]. The system is
composed of an Agilent 1100 series solvent delivery unit, an
ion-exchange column (G3154A, 150 4.6 mm, 3-mm particle
size; Agilent Technologies) and Agilent 7500CS ICP-MS series
connected by Agilent LC-ICP-MS connection kit (Agilent
Technologies).
Mobile phase
The mobile phase used consisted of 2 mM H3PO4 and 0.2 mM
EDTA-Na, with pH adjusted to 8.0 with 1 M NaOH, filtered
and degassed before analysis.
Sample preparation
An aliquot of 1-mL urine samples was filtered through
a 0.45-mm membrane filter (Nalgene, Rochester, New York,
USA). An aliquot of 0.2 mL of the filtered sample was
obtained and was diluted with four volumes of Milli-Q water
before analysis.Table 1 Concentrations of various arsenate metabolites in the
Dosage
(mg/L)
Animal
numbers
AsV (mg/L) AsIII (mg/L) Total inorga
(mg/L
0 15 <1 <1 <1
100 15 6.76 1.46a <1 6.76 1.
250 15 12.28 5.56a <1 12.28 5
500 15 27.37 7.04a <1 27.37 7
Values are means standard errors.
a Means significantly dose-related trend.
AsIIIZ arsenite; AsVZ arsenate; DMAVZ dimethylarsinic acid; MMAVZHPLC-ICP-MS analysis
Briefly, the column was equilibrated with the mobile phase
at a flow rate of 1.5 mL/min for at least 1 hour before any
sample injection. For sample analysis, an aliquot of 20 mL of
urine sample was injected with replication. The concen-
tration of each detected arsenic species was calculated
from an external standard calibration curve.
Statistics
Results are presented as means standard errors. Statis-
tical analysis was performed using SPSS 11.0 software (SPSS
Inc., Chicago, IL, USA). Differences in the level of urinary
arsenic species, composition percentage, and retention
percentage were analyzed by one-way analysis of variance
and post-hoc analysis least significant difference.Results
Exposure to the three different AsV dosages in the drinking
water had no significant effect on the growth of the mice
compared with that in the control animals (Fig. 1). The
mice drinking the AsV-containing water consumed a similar
amount of water compared with the mice drinking Milli-Q
water and appeared to be equally active and healthy. On
average, arsenic intakes were 13.0 mg/kg bw/d, 32.5 mg/kg
bw/d, and 65 mg/kg bw/d corresponding to the increasing
doses.
Concentrations of urinary arsenic species are summa-
rized in Table 1. Levels of AsV, DMAV, and total arsenic were
all significantly dose related. Both AsIII and MMAV were
under the detection limit. Two chromatograms overlaying
a standard solution of four arsenical compounds at 20 mg/L
and a mouse urinary arsenic speciation are shown in Fig. 2.
There were strong linear correlations among all the
urinary arsenic species and the original AsV concentration in
the drinking water. Correlation coefficients were 0.99,
0.97, and 0.98 for AsV, DMAV, and total As, respectively
(Fig. 3).
The relative percentages of urinary AsV and DMAV are
shown in Table 2. There was no statistical difference in the
percentage of neither DMAV nor AsV. The ratio of DMAV/AsV,
an index of methylation capability, appeared to show
a slight decrease in the 500-mg/L group compared with
those of other groups. However, there was no statistically
significant difference.
Water consumption (2.6 0.2 mL/animal/d) was quite
constant over the duration of the 2-month exposure. Total
As intakes could be derived by multiplying the original AsVurine of control and arsenate-exposed mice
nic As
)
DMAV (mg/L) MMAV (mg/L) Total As (mg/L)
9.76 2.00 <1 9.76 4.01
46a 121.76 7.70a <1 128.53 17.50a
.56a 194.34 28.84a <1 206.62 56.59a
.04a 329.37 30.55a <1 356.74 83.25a
monomethylarsonic acid.
Figure 2. Two overlaying chromatograms obtained from
a solution containing mixed standards of AsIII, DMAV, MMAV, and
AsV (bottom chromatogram), and a mouse urine sample
showing the DMAV and AsV peaks (top chromatogram). AsIIIZ
arsenite; AsVZ arsenate; DMAVZ dimethylarsinic acid;
MMAVZmonomethylarsonic acid.
Table 2 Percentage of various arsenate metabolites and
ratio of DMAV/AsV
Dosage
(mg/L)
Animal
numbers
AsV
(%)
DMAV
(%)
DMAV/AsV
(ratio)
0 15 d d d
100 15 5.2 0.9 94.8 0.9 20.7 4.6
250 15 5.5 1.9 94.4 1.9 20.9 5.7
500 15 7.2 1.1 92.7 1.1 14.1 2.2
Values are means standard errors.
AsVZ arsenate; DMAVZ dimethylarsinic acid.
420 H. Wu et al.concentrations in drinking water with the volume
consumed, which were calculated to be approximately
260 ng/animal/d, 650 ng/animal/d, and 1300 ng/animal/d.
The 24-hour total urinary arsenic excretion was calculated
by multiplying the total urinary As concentration by the
total urine volume collected in the metabolic cage for each
individual animal. Percentage of total urinary arsenic
excretion was significantly lower in the 500-mg/L group as
compared with that in the groups exposed to lower dosages
(Table 3). Correspondingly, the potential retention
percentage was, therefore, significantly higher (Fig. 4).Discussion
The level of exposure to iAs in animals or humans is often
estimated by the concentration of its metabolites in the0
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Figure 3. Linear correlation among urinary arsenic specia-
tion levels with original dosage. Data are expressed as mean
with standard error bar.urine [26]. It has been argued that the urinary level of
arsenic species metabolically related to iAs is more reliable
than the total urinary arsenic, which could contain high
levels of organoarsenic compounds derived from the die-
tary intake of seafood [27]. Indeed, for the control mice,
there was still detectable arsenic in the urine that origi-
nated from the diet. Although urinary arsenic reflects
exposure predominantly over the last 1e2 days [28], it has
been shown that the fraction of the various arsenic
metabolites in the urine are remarkably stable over
a period of about a week, indicating that an individual’s
methylation of iAs is stable over this time frame [29].
Assuming that the methylation patterns of the mice used in
the present experiments were stable over the study period,
the results showed that all arsenic metabolites increased
with increasing amounts of arsenic in the drinking water.
Although many epidemiological studies have shown
a good correlation between the intake estimate and
different indices of urinary arsenic metabolites, the highest
correlation between spot urinary indices and intake indices
only reached a correlation coefficient of 0.67 even with
careful questioning concerning consumption of fluids, well-
characterized arsenic level in water, and adjustments for
diuresis [28e31]. The strong linear relationships between
levels of different metabolites and the original exposure
dosage observed in this experiment confirm the validity of
using the metabolites of arsenic as a biomarker of internal
dose and potential biological effects.
Female C57BL/6J black mice appear to possess a highly
efficient methylation capability; DMAV accounts for more
than 90% of the total urine arsenic, which is greater than
the 80% reported in the male Naval Medical Research
Institute mice after a singe dose of arsenate, 0.04 mg/kg
bw, by intravenous injection [17]. In another study by
Csanaky and Gregus [32], Carworth Farms Lane Petter mice
were injected with a single dose of AsV (3.75 mg/kg bw,
intravenously), and urine was collected immediately for
2-hour cumulative urinary excretion of arsenic metabolites.
DMAV, AsV, and AsIII were 1.79%, 62.69%, and 35.30%,
respectively. The observed difference may be caused by
a difference in the dosage/exposure regimen used and/or
interspecies variation. Other factors, such as gender and
age, could also have an influence.
Many factors could influence the capability of arsenic
methylation in animals. The possible effects of the dose
level of arsenic on the methylation have been extensively
reviewed [33], and it has been proposed that the enzyme
methyltransferase could be saturated at high arsenic
Table 3 Percentage of urinary total As excretion and potential As retention in test groups
Dosage
(mg/L)
Water consumption
(mL/animal/d)
Average As intake
(ng/animal/d)
24-hr total urinary
As excretion
(ng/animal/d)
Percentage
of urinary
excretion (%)
Percentage
of retention (%)
100 2.6 0.2 260 159.04 9.89a 61.17 3.80b 38.83 3.80c
250 2.6 0.2 650 170.02 19.23a 26.16 2.95 73.84 2.95
500 2.6 0.2 1300 360.36 56.94a 27.72 4.38 72.28 4.38
Values are means standard errors.
a Significantly dose related (p< 0.05).
b Significantly greater than the other two groups (p< 0.05).
c Significantly lesser than the other two groups (p< 0.05).
AsZ arsenic.
Subchronic exposure of arsenic to mice 421exposure levels, which would lead to increased risk of
health effects. Indeed, in cases of acute arsenic intoxica-
tion, the excretion of methylated metabolites of arsenic is
delayed [34]. When comparing studies on urinary arsenic
metabolites in people exposed to arsenic occupationally,
experimentally, or through drinking water, with the general
public exposed to much lower arsenic levels in the envi-
ronment, there is no major difference in the average
methylation efficiencies [35]. Most population groups
studied so far have an average of 10e30% iAs, 10e20% MMA,
and 60e70% DMA in their urine samples. Our results are
consistent with this observation as the relative proportion
of DMAV and AsV are similar in the three groups. Thus, it can
be concluded that the level of exposure to arsenic has little
influence on the methylation efficiency.
Notwithstanding, ratio of DMAV/AsV, an index for the
methylation capability, decreased slightly in the 500-mg/L
group. Generally, a low fraction of DMA in the urine is
associated with a low overall rate of excretion, and thus,
a higher retention in tissues [33]. We found that the
retention percentage of 500 mg/L group was significantly
higher than those in the lower-dosed groups. Besides urine,
arsenic could also be excreted through other pathways,
such as feces, milk, hair, nail, and other body fluids,
although they account for only a very small fraction.0
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Figure 4. Relative percentage of total urinary As excretion
and retention under different dosages of arsenate exposure.
*p< 0.05. AsZ arsenic.However, feces may be an important pathway when
the arsenic bioavailability is low. We did not measure the
arsenic excretion through these pathways, but the
percentage could be an index of potential tissue retention.
In contrast, other studies have indicated a slight decrease
in the relative amount of DMA in urine and a corresponding
increase in the relative amount of MMA with increasing
exposure to arsenic through drinking water [36e38]. The
study by Ng et al. [39] examined the metabolite profile of
three groups of workers after occupational exposure to
arsenic at three copper chrome arsenate timber treatment
companies. One group of workers showed elevated levels of
iAs in their urine, and the results suggested that the
methylation capacity of these individuals was compro-
mised. This was the first reported case of elevated
concentrations of iAs in the urine profile of occupationally
exposed workers. Interestingly, the levels reported in the
workers were similar to those found in the urine of young
children who lived in an arsenic-endemic area of northern
Argentina [40]. Another study indicated that there were no
significant differences in the total inorganic urinary arsenic
levels between a control group and an exposed group of ion
implanter maintenance engineers, but the MMA content
was significantly higher in the exposed group [41]. It
remains unclear whether compromised liver function,
which could be at least in part caused by the exposure to
arsenic, was responsible for the observed alteration in the
arsenic methylation profile.
Other factors that may influence the methylation of
arsenic in humans are age, gender, smoking, and nutrition.
It was also found that women had a significantly higher DMA
percentage and lower MMA percentage than men, sug-
gesting that women may possess a more efficient methyl-
ation capability than men [25,42,43]. Elderly residents of
the blackfoot diseaseeendemic area showed a poor meth-
ylation ability of arsenic species in their urine, and this was
attributed to old age [42]. However, age was found not to
be related to the capability to metabolize iAs in a study by
Shraim et al. [25]. Nutritional status may also be an
important factor. For example, higher selenium levels
increased the disposition of arsenic and its methylation
capability, resulting in an increase of total urinary arsenic
and ratio of DMA/MMA. However, excessive intake of sele-
nium can inhibit methyltransferase, and thus, may alter
the disposition and methylation capability [25,44,45]. The
difference in the methylation capabilities in different
populations may sometimes be attributable to genetic
422 H. Wu et al.polymorphism. However, the specific genes for arsenic
methylation are still unclear at this stage.
In conclusion, the urinary arsenic speciation profile
could be used as a biomarker of internal dose as levels of all
detectable arsenic species showed strong linear correlation
with the original dosage. Methylation capability was similar
in all three groups of mice with a slight decrease in the
highest 500 mg/L group with respect to the ratio of DMAV/
AsV. This may result in greater arsenic retention in tissues
and may cause subsequent severe adverse biological
effects, especially cancer. The difference in methylation
capacities between human beings and mice should be taken
into account when interpreting or extrapolating experi-
mental results obtained using mice as the animal model.
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